A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

Exclusion Criteria

• •Have received, within the last 30 days, an investigational product as part of a clinical trial, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• •Persons who have previously completed or withdrawn from study investigating baricitinib, and have previously received the investigational product
• •Women with a positive pregnancy test or who are lactating
• •Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to admission to the clinical research unit) of a clinically significant bacterial, fungal, parasitic, viral (excluding rhinopharyngitis), or mycobacterial infection
• •Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose
• •Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
• •Have been exposed to a live vaccine within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study
• •Show evidence of acute or chronic liver disease
• •Show evidence of hepatitis B and/or positive hepatitis B and/or positive hepatitis B surface antigen
• •Show evidence of hepatitis C and/or positive hepatitis C antibody
• •Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study
• •Have creatinine clearance less than or equal to 50 milliliter per minute (mL/min) using the Cockcroft and Gault formula
• •Show evidence of spontaneous bacterial peritonitis within 6 month of dosing
• •Have had variceal bleeding within 3 months of check in
• •Show evidence of severe hyponatremia (sodium less than 120 millimolar per liter (mmol/L)
• •Have severe encephalopathy (Grade 3 to 4)
• •Have moderate to severe ascites (moderately hepatically impaired participants only)
• •Show presence of a portal shunt
• •Have hemoglobin less than 9.0 grams per deciliter (g/dL)
• •Have serum bilirubin greater than 15 milligrams per deciliter (mg/dL)